Upon soy consumption, isoflavones reach exposure levels in human breast tissue at which ERβ agonistic, putative protective, effects may occur. Yet, the clinical implications of these findings require further investigation. This project aims to characterize the differential activation of estrogen-responsive genes between dietary isoflavones and chemopreventive therapeutics in women undergoing breast reduction surgery by a controlled dietary intervention trial.